{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:41:34Z","timestamp":1773135694399,"version":"3.50.1"},"reference-count":29,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK61212"],"award-info":[{"award-number":["U01-DK61212"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK61230"],"award-info":[{"award-number":["U01-DK61230"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK61239"],"award-info":[{"award-number":["U01-DK61239"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK61242"],"award-info":[{"award-number":["U01-DK61242"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that glycemic failure rates were significantly lower in youth randomized to metformin plus rosiglitazone treatment than in youth randomized to metformin alone or metformin plus intensive lifestyle intervention. At the end of the study, rosiglitazone was permanently discontinued, and routine diabetes care resumed. Herein, we report postintervention glycemic failure rates in TODAY participants over an additional 36 months of follow-up for the three original treatment arms and describe insulin sensitivity and \u03b2-cell function outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>A total of 699 participants were randomized during TODAY, of whom 572 enrolled in the TODAY2 observational follow-up. Glycemic failure was defined as HbA1c \u22658% over a 6-month period, inability to wean from temporary insulin therapy within 3 months after acute metabolic decompensation during TODAY, or sustained HbA1c \u22658% over two consecutive visits during TODAY2. Oral glucose tolerance tests were conducted, and insulin sensitivity, insulinogenic index, and oral disposition index were calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>During the 36 months of TODAY2, glycemic failure rates did not differ among participants by original treatment group assignment. Insulin sensitivity and \u03b2-cell function deteriorated rapidly during the 36 months of TODAY2 routine diabetes care but did not differ by treatment group assignment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The added benefit of preventing glycemic failure by using rosiglitazone as a second agent in youth-onset type 2 diabetes did not persist after its discontinuation. More work is needed to address this rapid progression to avoid long-term diabetes complications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc20-0622","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T03:05:17Z","timestamp":1605063917000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":13,"title":["Postintervention Effects of Varying Treatment Arms on Glycemic Failure and \u03b2-Cell Function in the TODAY Trial"],"prefix":"10.2337","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct00081328","registry":"10.18810\/clinical-trials-gov"}],"author":[{"name":"The TODAY Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"2022031222414578200_B1","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.2337\/dc19-S013","article-title":"13. Children and adolescents: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031222414578200_B2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pedi.12719","article-title":"ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth","volume":"19","author":"Zeitler","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2022031222414578200_B3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031222414578200_B4","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1109333","article-title":"A clinical trial to maintain glycemic control in youth with type 2 diabetes","volume":"366","author":"Zeitler","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031222414578200_B5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2337\/dc12-2393","article-title":"Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and \u03b2-cell function in TODAY","volume":"36","author":"TODAY Study Group","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031222414578200_B6","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2337\/dc11-0423","article-title":"Declining \u03b2-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth","volume":"34","author":"Burns","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031222414578200_B7","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc15-0848","article-title":"HbA1c after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes","volume":"38","author":"Zeitler","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031222414578200_B8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1399-5448.2007.00237.x","article-title":"Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes","volume":"8","author":"Zeitler","year":"2007","journal-title":"Pediatr Diabetes"},{"key":"2022031222414578200_B9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1399-5448.2011.00846.x","article-title":"Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study","volume":"13","author":"Laffel","year":"2012","journal-title":"Pediatr Diabetes"},{"key":"2022031222414578200_B10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5448.2011.00841.x","article-title":"Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study","volume":"13","author":"Bacha","year":"2012","journal-title":"Pediatr Diabetes"},{"key":"2022031222414578200_B11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/gim.2017.150","article-title":"Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial","volume":"20","author":"Kleinberger","year":"2018","journal-title":"Genet Med"},{"key":"2022031222414578200_B12","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031222414578200_B13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1399-5448.2012.00915.x","article-title":"Progressive deterioration of \u03b2-cell function in obese youth with type 2 diabetes","volume":"14","author":"Bacha","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"2022031222414578200_B14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/pedi.12953","article-title":"Rapid progression of type 2 diabetes and related complications in children and young people-a literature review","volume":"21","author":"Barrett","year":"2020","journal-title":"Pediatr Diabetes"},{"key":"2022031222414578200_B15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.296.4.421","article-title":"Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians","volume":"296","author":"Pavkov","year":"2006","journal-title":"JAMA"},{"key":"2022031222414578200_B16","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2337\/dc12-2420","article-title":"Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial","volume":"36","author":"TODAY Study Group","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031222414578200_B17","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2337\/dc12-2387","article-title":"Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial","volume":"36","author":"TODAY Study Group","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031222414578200_B18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1464-5491.2008.02496.x","article-title":"Microvascular disease: what does the UKPDS tell us about diabetic nephropathy","volume":"25","author":"Bilous","year":"2008","journal-title":"Diabet Med"},{"key":"2022031222414578200_B19","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"2022031222414578200_B20","first-page":"et al","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume-title":"N Engl J Med","author":"Action to Control Cardiovascular Risk in Diabetes Study","year":"2008"},{"key":"2022031222414578200_B21","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031222414578200_B22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031222414578200_B23","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031222414578200_B24","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","article-title":"Thiazolidinedione use and bone loss in older diabetic adults","volume":"91","author":"Schwartz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222414578200_B25","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archinternmed.2012.1938","article-title":"Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes","volume":"172","author":"Idris","year":"2012","journal-title":"Arch Intern Med"},{"key":"2022031222414578200_B26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2337\/dc09-1579","article-title":"Effect of rosiglitazone and Ramipril on \u03b2-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial","volume":"33","author":"Hanley","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031222414578200_B27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00125-010-1985-4","article-title":"Long-term effect of rosiglitazone and\/or ramipril on the incidence of diabetes","volume":"54","author":"Gerstein","year":"2011","journal-title":"Diabetologia"},{"key":"2022031222414578200_B28","first-page":"1670","article-title":"Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on \u03b2-cell function: comparison of responses in youth and adults","volume":"68","author":"RISE Consortium","year":"2019","journal-title":"Diabetes"},{"key":"2022031222414578200_B29","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2337\/dc18-0787","article-title":"Impact of insulin and metformin versus metformin alone on \u03b2-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes","volume":"41","author":"RISE Consortium","year":"2018","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc20-0622","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/1\/75\/532420\/dc200622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/1\/75\/532420\/dc200622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:57:51Z","timestamp":1647133071000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/44\/1\/75\/33164\/Postintervention-Effects-of-Varying-Treatment-Arms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,10]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-0622","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}